Next Article in Journal
Cancer Diagnosis by Neural Network Analysis of Data from Semiconductor Sensors
Previous Article in Journal
Determinants of the Cardiovascular Capacity of Amateur Long-Distance Skiers during the Transition Period
Article

Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable

1
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
2
Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
3
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
4
Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
5
Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
6
Research Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
7
Department of Radiology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
8
Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
9
Department of Neurosurgery, University Hospital Brno, and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
10
Department of Neurosurgery, St. Anne’s University Hospital Brno, 656 91 Brno, Czech Republic
11
Department of Neurosurgery, St. Anne’s University Hospital Brno, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
12
Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
13
First Department of Pathology, St. Anne’s University Hospital and Faculty of Medicine, Masaryk University, 656 91 Brno, Czech Republic
14
Department of Pathological Physiology, Faculty of Medicine, Gamma Delta T Cell Laboratory, Masaryk University, 625 00 Brno, Czech Republic
15
Department of Biology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(9), 676; https://doi.org/10.3390/diagnostics10090676
Received: 31 July 2020 / Revised: 2 September 2020 / Accepted: 3 September 2020 / Published: 5 September 2020
(This article belongs to the Section Medical Imaging)
Background: The aim of this retrospective study is to assess the incidence, localization, and potential predictors of rapid early progression (REP) prior to initiation of radiotherapy in newly diagnosed glioblastoma patients and to compare survival outcomes in cohorts with or without REP in relation to the treatment. Methods: We assessed a consecutive cohort of 155 patients with histologically confirmed irradiated glioblastoma from 1/2014 to 12/2017. A total of 90 patients with preoperative, postoperative, and planning MRI were analyzed. Results: Median age 59 years, 59% men, and 39 patients (43%) underwent gross total tumor resection. The Stupp regimen was indicated to 64 patients (71%); 26 patients (29%) underwent radiotherapy alone. REP on planning MRI performed shortly prior to radiotherapy was found in 46 (51%) patients, most often within the surgical cavity wall, and the main predictor for REP was non-radical surgery (p < 0.001). The presence of REP was confirmed as a strong negative prognostic factor; median overall survival (OS) in patients with REP was 10.7 vs. 18.7 months and 2-year survival was 15.6% vs. 37.7% (hazard ratio HR 0.53 for those without REP; p = 0.007). Interestingly, the REP occurrence effect on survival outcome was significantly different in younger patients (≤ 50 years) and older patients (> 50 years) for OS (p = 0.047) and non-significantly for PFS (p = 0.341). In younger patients, REP was a stronger negative prognostic factor, probably due to more aggressive behavior. Patients with REP who were indicated for the Stupp regimen had longer OS compared to radiotherapy alone (median OS 16.0 vs 7.5; HR = 0.5, p = 0.022; 2-year survival 22.3% vs. 5.6%). The interval between surgery and the initiation of radiotherapy were not prognostic in either the entire cohort or in patients with REP. Conclusion: Especially in the subgroup of patients without radical resection, one may recommend as early initiation of radiotherapy as possible. The phenomenon of REP should be recognized as an integral part of stratification factors in future prospective clinical trials enrolling patients before initiation of radiotherapy. View Full-Text
Keywords: glioblastoma; chemotherapy; radiotherapy; rapid early progression; overall survival glioblastoma; chemotherapy; radiotherapy; rapid early progression; overall survival
Show Figures

Figure 1

MDPI and ACS Style

Lakomy, R.; Kazda, T.; Selingerova, I.; Poprach, A.; Pospisil, P.; Belanova, R.; Fadrus, P.; Smrcka, M.; Vybihal, V.; Jancalek, R.; Kiss, I.; Muckova, K.; Hendrych, M.; Knight, A.; Sana, J.; Slampa, P.; Slaby, O. Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable. Diagnostics 2020, 10, 676. https://doi.org/10.3390/diagnostics10090676

AMA Style

Lakomy R, Kazda T, Selingerova I, Poprach A, Pospisil P, Belanova R, Fadrus P, Smrcka M, Vybihal V, Jancalek R, Kiss I, Muckova K, Hendrych M, Knight A, Sana J, Slampa P, Slaby O. Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable. Diagnostics. 2020; 10(9):676. https://doi.org/10.3390/diagnostics10090676

Chicago/Turabian Style

Lakomy, Radek, Tomas Kazda, Iveta Selingerova, Alexandr Poprach, Petr Pospisil, Renata Belanova, Pavel Fadrus, Martin Smrcka, Vaclav Vybihal, Radim Jancalek, Igor Kiss, Katarina Muckova, Michal Hendrych, Andrea Knight, Jiri Sana, Pavel Slampa, and Ondrej Slaby. 2020. "Pre-Radiotherapy Progression after Surgery of Newly Diagnosed Glioblastoma: Corroboration of New Prognostic Variable" Diagnostics 10, no. 9: 676. https://doi.org/10.3390/diagnostics10090676

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop